Background The development of novel oral anticoagulants (NOACs) has changed the
landscape of non-valvular atrial fibrillation (NVAF) management. In this study, the …

Aims There are conflicting signals in the literature about comparative safety and
effectiveness of direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (NVAF) …

Background and Purpose: This study aimed to evaluate the comparative efficacy and safety
of 4 non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in Asians with non …

Background Whether non–vitamin K antagonist oral anticoagulants (NOAC s) are superior to
warfarin among Asians with nonvalvular atrial fibrillation remains unclear. Methods and …

The role of non-vitamin K antagonist oral anticoagulants (NOACs) in stroke prevention
remains unclear in Asian patients with atrial fibrillation (AF). Therefore, we performed a meta …

BACKGROUND Most of the randomized clinical trials that led to the wide use of non-vitamin
K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation (AF) …

Background: Given the huge burden of atrial fibrillation (AF) and AF-related stroke in Asia,
stroke prevention represents an urgent issue in this region. We herein performed a network …

Background Although randomized trials provide a high level of evidence regarding the
efficacy of non-vitamin K oral anticoagulants (NOACs), the results of such trials may differ …

Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …

Background Whether four direct oral anticoagulants (DOACs) are superior to warfarin in
Asian patients with nonvalvular atrial fibrillation (NVAF) remains unclear. Methods This …